ACTRN12624000374561招募中1 期
A Phase I, Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of OXT-328 in Healthy Adult Volunteers
Cleothena Enterprises Pty Ltd0 个研究点目标入组 56 人开始时间: 2024年4月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Participants will be included in Part A and B of the study only if they satisfy all the following criteria:
- •1. Must have given written informed consent, before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
- •2. Healthy male or female, aged between 18 and 65 years, inclusive at screening.
- •3. Body mass index (BMI) of 18 to 35 kg/m2, inclusive at screening, with body weight greater than or equal to 50.0 kg (males) or greater than or equal to 45.0 kg (females), at screening.
- •4. Participant is medically healthy (in the opinion of the Investigator [or delegate]), as determined by pre-study medical history and without clinically significant abnormalities including:
- •a. Physical examination without any additional clinically relevant findings
- •b. Systolic blood pressure (BP) in the range of 90 to 160 mmHg and diastolic BP in the range of 50 to 95 mmHg after 5 minutes in supine or semi-supine position.
- •c. Pulse rate in the range of 40 to 100 beats/minute after 5 minutes rest in supine or semi-supine position.
- •d. Body temperature between 35.5°C and 37.7°C.
- •e. Electrocardiogram without clinically significant abnormalities including QT interval corrected for Fredericia (QTcF) < 450 msec for male subjects and < 470 msec for female subjects.
- •f. No clinically significant findings in serum chemistry, haematology or urinalysis (in the opinion of the Investigator).
- •Note: The above assessments may be repeated, if abnormal values were recorded in the first instance, at the discretion of the Investigator (or delegate).
- •5. Participant is willing to refrain from consuming food or beverages containing caffeine and/or xanthene products, within 24 hours prior to check-in on Day -1 and while confined to the study clinic.
- •6. Female participants must be of non-childbearing potential i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the screening visit) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone [FSH] level consistent with postmenopausal status, per local laboratory guidelines), or, if of childbearing potential:
- •a. Must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on Day -1, prior to dose administration.
- •b. Must agree not to donate ova or attempt to become pregnant from the time of signing consent until at least 30 days after the last dose of study drug.
- •c. If not exclusively in a same-sex relationship, must agree to use adequate contraception (which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception) from one month prior to screening until at least 30 days after the last dose of study drug.
- •7. Male participants must:
- •a. Agree not to donate sperm from the time of signing consent until at least 90 days after the last dose of study drug.
- •b. If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as use of a condom plus a highly effective method of contraception) from the time of signing consent until at least 90 days after the last dose of study drug.
- •c. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, agree to use a con
排除标准
- •Participants will be excluded from Part A and B of the study if there is evidence of any of the following:
- •1. Current, active infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.
- •2. Suffers from frequent or recurrent infections (defined as greater than or equal to 3 recurrent or separate occurrences in the 12 months preceding first study drug administration or 2 recurrent or separate occurrences in the 6 months preceding first study drug administration).
- •3. Use of antioxidant-containing medications, supplements or products within 30 days prior to the first study drug administration.
- •4. Use of systemic corticosteroid, sulindac, or any other NSAID within 7 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration.
- •5. Use of tricyclics, serotonin and norepinephrine reuptake inhibitors (SNRIs) (e.g., duloxetine, venlafaxine), sodium channel blockers, and gabapentinoids within 30 days or 5 half-lives of the medication (whichever is longer) prior to first study drug administration.
- •6. Use of selective serotonin reuptake inhibitors (SSRIs) (citalopram, escitalopram, sertraline, etc.) within 30 days prior to the first study drug administration.
- •Note: Participant on stable doses of SSRIs is permitted.
- •7. Experienced myocardial infarction or undergone coronary artery bypass grafting within 6 months of Screening.
- •8. Diagnosis with congestive heart failure, defined as New York Heart Association (NYHA) Class II-IV.
- •9. History of hypersensitivity reaction, anaphylaxis or other clinically significant reactions or known allergy to any of the study drug ingredients (including any of its metabolic derivatives – sulindac, sulindac sulfone and sulindac sulfide), or any other NSAIDs.
- •10. History of or currently existing aspirin-induced asthma, gastric ulcers, non-iatrogenic intestinal perforation, or GI bleeding from NSAID usage for which intervention was required.
- •11. History of any clinically significant disorder (which, in the opinion of the Investigator [or delegate] would make implementation of the protocol or interpretation of study results difficult, or that would put the subject at risk by participating in the study), including cardiovascular, haematologic, pulmonary, hepatic, renal, GI, connective tissue, uncontrolled endocrine/metabolic (including but not limited to diabetes), oncologic (within the last 5 years), neurologic, and psychiatric (including substance abuse disorder), or any disorder that may prevent the successful completion of the study or influence the absorption, distribution, metabolism, excretion, or action of the study drug (including any of its metabolic derivatives – sulindac, sulindac sulfone and sulindac sulfide).
- •Note: Participants with history of resolved childhood asthma, history of migraine (if less than or equal to 1 monthly episode and not on preventative medication), or history of non-hospitalised depression (if not on any anti-depressant) will be allowed to participate in the study.
- •12. History of surgery or hospitalisation within 12 weeks prior to screening, or surgery planned during the study.
- •13. Lack of suitable veins for multiple venepunctures/cannulations as assessed by the Investigator or delegate at screening.
- •14. Presence of any tattoos, scarring or active skin infection or other condition (including open sores, pressure ulcers, stasis ulcers, or other dermatitides), which (in the opinion of
研究者
相似试验
尚未招募
1 期
A Phase I, Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of OXT-328 in Patients with Chemotherapy-Induced Peripheral Neuropathy. (Part C)Chemotherapy-Induced Peripheral Neuropathy (CIPN)Neurological - Other neurological disordersACTRN12624000473561Cleothena Enterprises Pty Ltd20
招募中
1 期
A Phase I Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect of Food on the Bioavailability of SKY-0515 in Healthy Volunteers and Patients with Huntington’s DiseaseHuntington’s DiseaseHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12624000602527Skyhawk Therapeutics, Inc74
招募中
1 期
A Phase I Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamicsand Effect of Food on the Bioavailability of SKY-0515 in Healthy VolunteersHuntington's DiseaseNeurological - Neurodegenerative diseasesHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersACTRN12623001161617Skyhawk Therapeutics, Inc.168
已完成
1 期
A Phase I, Randomised, Double-Blind, Placebo-Controlled,AscendingSingle- and Repeat-Dose Study of the Safety,Tolerability andPharmacokinetics of Orally Administered PRN473.ACTRN12613000951752Clinical Network Services114
进行中（未招募）
1 期
The second healthy volunteer study assessing the safety, tolerability, and pharmacokinetics (blood levels) of gerilimzumab against placebo.Rheumatoid ArthritisACTRN12615001141538Clinical Network Services Pty Ltd18